Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  FIRST NORTH STOCKHOLM  >  Biovica International AB (publ)    BIOVIC B   SE0008613731

BIOVICA INTERNATIONAL AB (PUBL)

(BIOVIC B)
  Report
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed First North Stockholm
08/06/2020 08/07/2020 08/10/2020 08/11/2020 08/12/2020 Date
23.9(c) 24(c) 23.2(c) 24.5(c) 23.5 Last
9 128 38 779 9 805 23 406 5 889 Volume
-1.24% +0.42% -3.33% +5.60% -4.08% Change
More quotes
Financials
Sales 2020 3,00 M 0,34 M 0,34 M
Net income 2020 -28,4 M -3,23 M -3,23 M
Net cash position 2020 37,0 M 4,21 M 4,21 M
P/E ratio 2020 -15,3x
Yield 2020 -
Sales 2021 19,5 M 2,22 M 2,22 M
Net income 2021 -32,5 M -3,70 M -3,70 M
Net cash position 2021 6,50 M 0,74 M 0,74 M
P/E ratio 2021 -17,7x
Yield 2021 -
Capitalization 578 M 66,0 M 65,8 M
EV / Sales 2020 180x
EV / Sales 2021 29,3x
Nbr of Employees 17
Free-Float 70,3%
More Financials
Company
Biovica International AB is a Sweden-based biotechnology company. It develops and commercializes blood-based biomarker assays for the monitoring of cancer therapies and for prediction of patient outcome. The Company has focus on breast cancer and its main product DiviTum is a blood-based test, which measures the activity of the enzyme thymidine kinase-1 (TK) in blood serum or cell cultures. The Company collaborates... 
More about the company
Latest news on BIOVICA INTERNATIONAL AB (
07/22BIOVICA INTERNATIONAL PUBL : Notice to AGM for Biovica International AB
AQ
06/30BIOVICA INTERNATIONAL AB : – Annual Report for the fiscal year 2019/2020 p..
AQ
06/17BIOVICA INTERNATIONAL PUBL : completes analytical validation as part of FDA appl..
AQ
06/05Biovica Year-end Report for 2019/2020
AQ
05/22BIOVICA INTERNATIONAL PUBL : DiviTum® acknowledged in ASCO educational book
AQ
05/11BIOVICA INTERNATIONAL PUBL : DiviTum® and TK activity acknowledged in highly ren..
AQ
05/11BIOVICA INTERNATIONAL PUBL : provides market share target at today's Capital Mar..
AQ
05/06REMINDER : Biovica invites to virtual Capital Markets Day 11 May
AQ
05/06REMINDER : Biovica invites to virtual Capital Markets Day 11 May
AQ
05/06REMINDER : Biovica invites to virtual Capital Markets Day 11 May
AQ
05/06REMINDER : Biovica invites to virtual Capital Markets Day 11 May
AQ
04/29BIOVICA INTERNATIONAL PUBL : invites to virtual Capital Markets Day 11 May
AQ
04/08BIOVICA INTERNATIONAL PUBL : initiates a collaboration with Mayo Clinic to study..
AQ
03/25BIOVICA INTERNATIONAL PUBL : strengthens its commercial leadership
AQ
03/12BIOVICA INTERNATIONAL PUBL : DiviTum - first study published on CDK4/6 inhibitor..
AQ
More news
News in other languages on BIOVICA INTERNATIONAL AB (
07/22BIOVICA INTERNATIONAL PUBL : Notice to AGM for Biovica International AB
06/30BIOVICA INTERNATIONAL AB : – Annual Report for the fiscal year 2019/2020 p..
06/17BIOVICA INTERNATIONAL PUBL : completes analytical validation as part of FDA appl..
06/05Biovica Year-end Report for 2019/2020
05/22BIOVICA INTERNATIONAL PUBL : DiviTum® acknowledged in ASCO educational book
More news
Chart BIOVICA INTERNATIONAL AB (PUBL)
Duration : Period :
Biovica International AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts 2
Average target price 31,00 SEK
Last Close Price 24,50 SEK
Spread / Highest target 26,5%
Spread / Average Target 26,5%
Spread / Lowest Target 26,5%
EPS Revisions
Managers
NameTitle
Anders Rylander Chief Executive Officer & Director
Lars Erik Holmqvist Chairman
Adam Germunder Operations Director
Cecilia Driving CFO, Head-Human Resource, IR & EVP
Mattias Bergqvist Director-Clinical Development
Sector and Competitors